自己資本利益率 (ROE)
2005年以降
計算
Gilead Sciences Inc.、 ROE、長期トレンド計算
| ROE | = | 100 | × | ギリアド社に帰属する当期純利益(損失)1 | ÷ | ギリアド社株主資本合計1 | |
|---|---|---|---|---|---|---|---|
| 2023/12/31 | 24.81% | = | 100 | × | 5,665) | ÷ | 22,833) |
| 2022/12/31 | 21.62% | = | 100 | × | 4,592) | ÷ | 21,240) |
| 2021/12/31 | 29.55% | = | 100 | × | 6,225) | ÷ | 21,069) |
| 2020/12/31 | 0.68% | = | 100 | × | 123) | ÷ | 18,202) |
| 2019/12/31 | 23.91% | = | 100 | × | 5,386) | ÷ | 22,525) |
| 2018/12/31 | 25.51% | = | 100 | × | 5,455) | ÷ | 21,387) |
| 2017/12/31 | 22.64% | = | 100 | × | 4,628) | ÷ | 20,442) |
| 2016/12/31 | 71.48% | = | 100 | × | 13,501) | ÷ | 18,887) |
| 2015/12/31 | 97.70% | = | 100 | × | 18,108) | ÷ | 18,534) |
| 2014/12/31 | 78.45% | = | 100 | × | 12,101) | ÷ | 15,426) |
| 2013/12/31 | 27.05% | = | 100 | × | 3,075) | ÷ | 11,369) |
| 2012/12/31 | 27.84% | = | 100 | × | 2,592) | ÷ | 9,310) |
| 2011/12/31 | 41.60% | = | 100 | × | 2,804) | ÷ | 6,739) |
| 2010/12/31 | 49.48% | = | 100 | × | 2,901) | ÷ | 5,864) |
| 2009/12/31 | 41.40% | = | 100 | × | 2,636) | ÷ | 6,367) |
| 2008/12/31 | 48.43% | = | 100 | × | 2,011) | ÷ | 4,152) |
| 2007/12/31 | 46.69% | = | 100 | × | 1,615) | ÷ | 3,460) |
| 2006/12/31 | -65.54% | = | 100 | × | (1,190) | ÷ | 1,816) |
| 2005/12/31 | 26.88% | = | 100 | × | 814) | ÷ | 3,028) |
レポートに基づく: 10-K (報告日: 2023-12-31), 10-K (報告日: 2022-12-31), 10-K (報告日: 2021-12-31), 10-K (報告日: 2020-12-31), 10-K (報告日: 2019-12-31), 10-K (報告日: 2018-12-31), 10-K (報告日: 2017-12-31), 10-K (報告日: 2016-12-31), 10-K (報告日: 2015-12-31), 10-K (報告日: 2014-12-31), 10-K (報告日: 2013-12-31), 10-K (報告日: 2012-12-31), 10-K (報告日: 2011-12-31), 10-K (報告日: 2010-12-31), 10-K (報告日: 2009-12-31), 10-K (報告日: 2008-12-31), 10-K (報告日: 2007-12-31), 10-K (報告日: 2006-12-31), 10-K (報告日: 2005-12-31).
1 百万米ドル
競合他社との比較
Gilead Sciences Inc.、 ROE、長期トレンド、競合他社との比較
| Gilead Sciences Inc. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Johnson & Johnson | Merck & Co. Inc. | Moderna Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023/12/31 | 24.81% | 46.94% | 107.78% | 27.27% | 8.91% | 48.65% | 51.11% | 0.97% | -34.03% | 2.38% | 15.22% | 12.83% |
| 2022/12/31 | 21.62% | 68.60% | 178.97% | 20.37% | 14.39% | 58.64% | 23.36% | 31.57% | 43.73% | 32.79% | 19.14% | 15.80% |
| 2021/12/31 | 29.55% | 74.91% | 87.96% | 19.46% | 14.24% | 62.16% | 28.20% | 34.17% | 86.26% | 28.47% | 43.03% | 18.94% |
| 2020/12/31 | 0.68% | 35.30% | 77.20% | -23.84% | 9.17% | 109.79% | 23.25% | 27.91% | -29.17% | 15.21% | 31.86% | 18.47% |
| 2019/12/31 | 23.91% | — | 81.07% | 6.66% | 9.94% | 319.09% | 25.42% | 37.99% | -43.75% | 25.77% | 19.08% | 12.45% |
| 2018/12/31 | 25.51% | — | 67.15% | 35.07% | 9.40% | 32.88% | 25.60% | 23.30% | -25.14% | 17.59% | 27.91% | 10.65% |
| 2017/12/31 | 22.64% | 104.16% | 7.84% | 8.58% | 9.45% | -1.76% | 2.16% | 6.97% | — | 29.47% | 19.51% | 8.76% |
| 2016/12/31 | 71.48% | 128.41% | 25.85% | 27.55% | 11.10% | 19.54% | 23.49% | 9.78% | — | 12.12% | 20.13% | 9.39% |
| 2015/12/31 | 97.70% | 130.39% | 24.71% | 10.97% | 14.17% | 16.53% | 21.66% | 9.94% | — | 10.75% | 17.40% | 9.25% |
| 2014/12/31 | 78.45% | 101.84% | 20.01% | 13.49% | 11.11% | 15.55% | 23.40% | 24.50% | — | 12.81% | 13.69% | 9.22% |
| 2013/12/31 | 27.05% | 91.90% | 23.00% | 16.91% | 12.04% | 26.57% | 18.68% | 8.85% | — | 28.83% | 21.74% | 7.55% |
| 2012/12/31 | 27.84% | 156.85% | 22.80% | 14.39% | 12.58% | 27.69% | 16.74% | 11.63% | — | 17.93% | 60.24% | 7.62% |
| 2011/12/31 | 41.60% | — | 19.35% | 23.25% | 12.85% | 32.11% | 16.94% | 11.50% | — | 12.18% | -45.65% | 8.84% |
| 2010/12/31 | 49.48% | — | 19.32% | 19.74% | 13.08% | 40.82% | 23.57% | 1.58% | — | 9.40% | -19.79% | 6.74% |
| 2009/12/31 | 41.40% | — | 20.32% | 71.49% | 9.90% | 45.45% | 24.25% | 21.85% | — | 9.59% | -17.10% | 5.51% |
| 2008/12/31 | 48.43% | — | 20.58% | 42.86% | 13.43% | -30.76% | 30.46% | 41.63% | — | 14.08% | -19.75% | 6.66% |
| 2007/12/31 | 46.69% | — | 17.72% | 20.50% | 15.08% | 21.61% | 24.41% | 18.01% | — | 12.53% | -22.94% | 5.25% |
| 2006/12/31 | -65.54% | — | 15.56% | 15.86% | 16.89% | 24.25% | 28.11% | 25.25% | — | 27.10% | -47.24% | 1.21% |
| 2005/12/31 | 26.88% | — | 17.96% | 26.77% | 17.67% | 18.34% | 27.49% | 25.85% | — | 12.32% | -83.72% | 7.99% |
レポートに基づく: 10-K (報告日: 2023-12-31), 10-K (報告日: 2022-12-31), 10-K (報告日: 2021-12-31), 10-K (報告日: 2020-12-31), 10-K (報告日: 2019-12-31), 10-K (報告日: 2018-12-31), 10-K (報告日: 2017-12-31), 10-K (報告日: 2016-12-31), 10-K (報告日: 2015-12-31), 10-K (報告日: 2014-12-31), 10-K (報告日: 2013-12-31), 10-K (報告日: 2012-12-31), 10-K (報告日: 2011-12-31), 10-K (報告日: 2010-12-31), 10-K (報告日: 2009-12-31), 10-K (報告日: 2008-12-31), 10-K (報告日: 2007-12-31), 10-K (報告日: 2006-12-31), 10-K (報告日: 2005-12-31).
産業部門との比較: 製薬、バイオテクノロジー、ライフサイエンス
Gilead Sciences Inc.、 ROE、長期トレンド、産業部門との比較: 製薬、バイオテクノロジー、ライフサイエンス
| Gilead Sciences Inc. | 製薬、バイオテクノロジー、ライフサイエンス | |
|---|---|---|
| 2023/12/31 | 24.81% | 18.83% |
| 2022/12/31 | 21.62% | 28.81% |
| 2021/12/31 | 29.55% | 31.93% |
| 2020/12/31 | 0.68% | 16.48% |
| 2019/12/31 | 23.91% | 27.56% |
| 2018/12/31 | 25.51% | 25.64% |
| 2017/12/31 | 22.64% | 14.60% |
| 2016/12/31 | 71.48% | 22.31% |
| 2015/12/31 | 97.70% | 21.69% |
| 2014/12/31 | 78.45% | 21.22% |
| 2013/12/31 | 27.05% | 20.56% |
| 2012/12/31 | 27.84% | 18.37% |
| 2011/12/31 | 41.60% | 15.55% |
| 2010/12/31 | 49.48% | 14.28% |
| 2009/12/31 | 41.40% | 20.65% |
| 2008/12/31 | 48.43% | 21.59% |
| 2007/12/31 | 46.69% | 17.30% |
| 2006/12/31 | -65.54% | 22.03% |
| 2005/12/31 | 26.88% | 19.22% |
レポートに基づく: 10-K (報告日: 2023-12-31), 10-K (報告日: 2022-12-31), 10-K (報告日: 2021-12-31), 10-K (報告日: 2020-12-31), 10-K (報告日: 2019-12-31), 10-K (報告日: 2018-12-31), 10-K (報告日: 2017-12-31), 10-K (報告日: 2016-12-31), 10-K (報告日: 2015-12-31), 10-K (報告日: 2014-12-31), 10-K (報告日: 2013-12-31), 10-K (報告日: 2012-12-31), 10-K (報告日: 2011-12-31), 10-K (報告日: 2010-12-31), 10-K (報告日: 2009-12-31), 10-K (報告日: 2008-12-31), 10-K (報告日: 2007-12-31), 10-K (報告日: 2006-12-31), 10-K (報告日: 2005-12-31).
業界との比較: 医療
Gilead Sciences Inc.、 ROE、長期トレンド、業界との比較: 医療
| Gilead Sciences Inc. | 医療 | |
|---|---|---|
| 2023/12/31 | 24.81% | 17.03% |
| 2022/12/31 | 21.62% | 22.88% |
| 2021/12/31 | 29.55% | 24.08% |
| 2020/12/31 | 0.68% | 15.82% |
| 2019/12/31 | 23.91% | 20.90% |
| 2018/12/31 | 25.51% | 17.33% |
| 2017/12/31 | 22.64% | 14.32% |
| 2016/12/31 | 71.48% | 17.89% |
| 2015/12/31 | 97.70% | 18.18% |
| 2014/12/31 | 78.45% | 18.66% |
| 2013/12/31 | 27.05% | 18.20% |
| 2012/12/31 | 27.84% | 17.48% |
| 2011/12/31 | 41.60% | 15.35% |
| 2010/12/31 | 49.48% | 14.63% |
| 2009/12/31 | 41.40% | 19.52% |
| 2008/12/31 | 48.43% | 18.97% |
| 2007/12/31 | 46.69% | 17.18% |
| 2006/12/31 | -65.54% | 20.41% |
| 2005/12/31 | 26.88% | 18.45% |
レポートに基づく: 10-K (報告日: 2023-12-31), 10-K (報告日: 2022-12-31), 10-K (報告日: 2021-12-31), 10-K (報告日: 2020-12-31), 10-K (報告日: 2019-12-31), 10-K (報告日: 2018-12-31), 10-K (報告日: 2017-12-31), 10-K (報告日: 2016-12-31), 10-K (報告日: 2015-12-31), 10-K (報告日: 2014-12-31), 10-K (報告日: 2013-12-31), 10-K (報告日: 2012-12-31), 10-K (報告日: 2011-12-31), 10-K (報告日: 2010-12-31), 10-K (報告日: 2009-12-31), 10-K (報告日: 2008-12-31), 10-K (報告日: 2007-12-31), 10-K (報告日: 2006-12-31), 10-K (報告日: 2005-12-31).